The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Jeffrey L. Cummings

Mary S. Easton Center for Alzheimer's Disease Research at UCLA

Los Angeles

CA 90095-7226

USA

[email]@*.ucla.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Los Angeles, CA 90095-7226, USA. 2010
  • Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, USA. 2010
  • Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, United States. 2009 - 2010
  • UCLA Alzheimer Disease Center, UCLA, Los Angeles, USA. 2007 - 2008
  • Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, USA. 2004 - 2008
  • Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, USA. 2003 - 2008
  • UCLA Alzheimer's Center, 10911 Weyburn Avenue, Suite 200, Los Angeles, USA. 2007
  • University of California, Los Angeles, Alzheimer's Disease Center, Los Angeles, USA. 2005

References

  1. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. Cummings, J., Emre, M., Aarsland, D., Tekin, S., Dronamraju, N., Lane, R. J. Alzheimers Dis. (2010) [Pubmed]
  2. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Cummings, J.L., Farlow, M.R., Meng, X., Tekin, S., Olin, J.T. Clin. Drug. Investig (2010) [Pubmed]
  3. Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis. Cummings, J., Jones, R., Wilkinson, D., Lopez, O., Gauthier, S., Waldemar, G., Zhang, R., Xu, Y., Sun, Y., Richardson, S., Mackell, J. J. Alzheimers Dis. (2010) [Pubmed]
  4. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. Cummings, J.L., Ferris, S.H., Farlow, M.R., Olin, J.T., Meng, X. Dement. Geriatr. Cogn. Disord (2010) [Pubmed]
  5. Integrating ADNI results into Alzheimer's disease drug development programs. Cummings, J.L. Neurobiol. Aging (2010) [Pubmed]
  6. Commentary on "a roadmap for the prevention of dementia II: Leon Thal Symposium 2008." Establishing a national biomarker database: utility and incentives. Cummings, J.L. Alzheimer's & Dementia : J. Alzheimer's Association (2009) [Pubmed]
  7. Defining and labeling disease-modifying treatments for Alzheimer's disease. Cummings, J.L. Alzheimer's & Dementia : J. Alzheimer's Association (2009) [Pubmed]
  8. Behavioral effects of current Alzheimer's disease treatments: a descriptive review. Cummings, J.L., Mackell, J., Kaufer, D. Alzheimers. Dement (2008) [Pubmed]
  9. Optimizing phase II of drug development for disease-modifying compounds. Cummings, J.L. Alzheimer's & Dementia : J. Alzheimer's Association (2008) [Pubmed]
  10. Controversies in Alzheimer's disease drug development. Cummings, J.L. Int. Rev. Psychiatry (2008) [Pubmed]
  11. Pharmacokinetic rationale for the rivastigmine patch. Cummings, J., Lefèvre, G., Small, G., Appel-Dingemanse, S. Neurology (2007) [Pubmed]
  12. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Cummings, J.L., Doody, R., Clark, C. Neurology (2007) [Pubmed]
  13. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Cummings, J., Winblad, B. Expert. Rev. Neurother (2007) [Pubmed]
  14. Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Cummings, J.L., Zhong, K. Nat. Rev. Drug. Discov (2006) [Pubmed]
  15. Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders. Cummings, J.L., McRae, T., Zhang, R. Am. J. Geriatr. Psychiatry (2006) [Pubmed]
  16. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Cummings, J.L., Schneider, E., Tariot, P.N., Graham, S.M. Neurology (2006) [Pubmed]
  17. ADCS Prevention Instrument Project: behavioral measures in primary prevention trials. Cummings, J.L., Raman, R., Ernstrom, K., Salmon, D., Ferris, S.H. Alzheimer. Dis. Assoc. Disord (2006) [Pubmed]
  18. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Cummings, J.L. Alzheimer's & Dementia : J. Alzheimer's Association (2006) [Pubmed]
  19. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Cummings, J.L., Koumaras, B., Chen, M., Mirski, D. Am. J. Geriatr. Pharmacother (2005) [Pubmed]
  20. Clinical evaluation as a biomarker for Alzheimer's disease. Cummings, J.L. J. Alzheimers Dis. (2005) [Pubmed]
  21. Fluctuations in cognitive function in dementia with Lewy bodies. Cummings, J.L. Lancet. Neurol (2004) [Pubmed]
  22. Alzheimer's disease. Cummings, J.L. N. Engl. J. Med. (2004) [Pubmed]
  23. Dementia with lewy bodies: molecular pathogenesis and implications for classification. Cummings, J.L. J. Geriatr. Psychiatry. Neurol (2004) [Pubmed]
  24. Alzheimer's disease: from molecular biology to neuropsychiatry. Cummings, J.L. Semin. Clin. Neuropsychiatry (2003) [Pubmed]
 
WikiGenes - Universities